Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

28.52
+0.44001.57%
Post-market: 28.00-0.5200-1.82%19:30 EDT
Volume:848.79K
Turnover:24.39M
Market Cap:3.24B
PE:-11.48
High:29.30
Open:28.46
Low:28.13
Close:28.08
52wk High:30.06
52wk Low:8.67
Shares:113.58M
Float Shares:108.11M
Volume Ratio:0.61
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:6.17
PE(LYR):-11.73

Loading ...

Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says

MT Newswires Live
·
Aug 18

Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration

Simply Wall St.
·
Aug 18

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

TIPRANKS
·
Aug 17

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

GlobeNewswire
·
Aug 17

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Replimune Q1 Net Loss Narrows as Expenses Decline

Reuters
·
Aug 14

Allarity Therapeutics Q2 Loss Narrows as Expenses Fall

Reuters
·
Aug 14

Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses

Reuters
·
Aug 14

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 14

NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track

Reuters
·
Aug 14

Elicio Therapeutics Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 14

PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall

Reuters
·
Aug 13

Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs

Reuters
·
Aug 13

Immunome Director Isaac Barchas Reports Disposal of Common Shares Worth $2.18 Million

Reuters
·
Aug 13

Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook

Reuters
·
Aug 13

Immunome Price Target Raised to $35.00/Share from $31.00 by Wedbush

Dow Jones
·
Aug 13

Evercore ISI Remains a Buy on Immunome (IMNM)

TIPRANKS
·
Aug 12

Immunome, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

TIPRANKS
·
Aug 12

Wedbush Adjusts Price Target on Immunome to $35 From $31, Keeps Outperform Rating

MT Newswires Live
·
Aug 12